Orchid Pharma Ltd

Orchid Pharma Earnings Call: Key Takeaways

Orchid Pharma reports FY26 standalone revenue of ₹811 Cr and PAT of ₹45 Cr, focusing on transitioning from a turnaround to an integrated cephalosporin platform with major capex in 7ACA.

Orchid Pharma Management Change

Orchid Pharma appointed M/s. T R Chadha & Co. LLP as its Internal Auditor for a 12-month term. The appointment strengthens the company's internal control and governance frameworks.

Execution

12 months

Orchid Pharma Q4 FY26 Results: Net Profit ₹23.8 Cr, Up 6.7% YoY

Orchid Pharma Ltd reported revenue from operations of ₹237.6 Cr (+0.0% YoY) and net profit of ₹23.8 Cr (+6.7% YoY) for Q4 FY26.

Key figure

Net profit ₹23.8 Cr · +6.7% YoY

Orchid Pharma Financial Results

Orchid Pharma approved audited FY2026 results and appointed T R Chadha & Co. LLP as internal auditors. The consolidated net profit for the year stood at ₹21.21 Crore.

Orchid Pharma Board Meeting Date

Orchid Pharma scheduled a board meeting for May 25, 2026, to approve fiscal 2026 audited financial results. The trading window remains closed until 48 hours post-declaration.

Orchid Pharma Fund Raise of ₹400 Cr

Orchid Pharma Limited submitted its Monitoring Agency Report for the Rs. 400 Crore QIP. The funds are being utilized as per revised shareholder-approved objects.

Value

₹400.0 Cr